Risk-benefit assessment of antiarrhythmic drugs. An epidemiological perspective.
Friedman
L
L
Clinical Trials Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Schron
E
E
Yusuf
S
S
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D002986:Clinical Trials as Topic; D006801:Humans; D008137:Longitudinal Studies; D011379:Prognosis; D012307:Risk Factors
D000889:Anti-Arrhythmia Agents